Daniela Bota

Daniela Bota is the Vice Dean for Clinical Research at the University of California, Irvine (UCI) School of Medicine and a Professor in the Department of Neurology. She directs the UCI Alpha Clinic at the Sue and Bill Gross Stem Cell Research Center and co-leads UCI Health's Comprehensive Brain Tumor Program. Her academic roles are complemented by leadership in translational research, clinical trial oversight, and bridging laboratory innovations to patient care.

Her research focuses on neuro-oncology, particularly advancing therapies for brain malignancies like glioblastoma. This includes pioneering stem-cell targeted treatments, immunotherapy (e.g., dendritic cell vaccines and checkpoint inhibitors), and medical devices such as tumor-treating fields (TTFields). She explores personalized medicine, overcoming chemotherapeutic resistance, and molecular mechanisms underlying tumor progression. Her work integrates genetic analysis, preclinical drug testing, and clinical trial design to address unmet needs in brain tumor treatment.

Dr. Bota’s recent articles emphasize novel therapeutic strategies, including LonP1 and MAGMAS inhibitors, phase II/III trials for drugs like mirdametinib and marizomib, and investigations into chemotherapy-induced neurotoxicity. She also evaluates combination therapies involving natural marine products and cognitive training for cancer-related impairment.

No scientific awards are explicitly mentioned in the provided text. Her contributions to translational research and clinical leadership are highlighted through her roles in managing large-scale trials, directing clinical programs, and training future researchers. She is affiliated with the Sue and Bill Gross Stem Cell Research Center and the Alpha Clinic, where she drives interdisciplinary efforts to integrate cutting-edge science with patient care.